{"transactions":[{"id":43551,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2807,"kind":"organization","name":"Merck & Co., Inc.","position":1,"cik":"0000310158","reported_name":"Merck & Co., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":11336,"kind":"organization","name":"MERCK SHARP & DOHME LLC","position":2,"cik":"0000064978","reported_name":"MERCK SHARP & DOHME LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001","published_at":"2024-03-11T19:27:05.000Z","date":"2024-03-11","kind":"purchase","planned":false,"acquired":true,"shares":21397205,"price":23,"value":492135715.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of January 7, 2024 by and among Merck Sharp & Dohme LLC, a wholly owned subsidiary of Merck & Co. Inc. (\"Parent\"), Hawaii Merger Sub, Inc., a wholly owned subsidiary of  Merck Sharp & Dohme LLC (\"Merger Sub\"), and Harpoon Therapeutics, Inc. (\"Harpoon\"), Merger Sub merged with and into Harpoon (the \"Merger\") on March 11, 2024. Upon completion of the Merger, each share of common stock of Harpoon that was issued and outstanding immediately prior to the effective time of the Merger was cancelled, and each share of common stock of Merger Sub was converted into one share of common stock of the surviving corporation."},{"field":"shares","element":"transactionShares","label":"F2","text":"(Continued from footnote 1) Consequently, upon the consummation of the Merger on March 11, 2024, Parent became the direct beneficial owner of 1,000 shares of common stock of the surviving corporation, representing 100% of the issued and outstanding shares of common stock of the surviving corporation. Merck & Co., Inc. is the indirect beneficial owner of such shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of January 7, 2024 by and among Merck Sharp & Dohme LLC, a wholly owned subsidiary of Merck & Co. Inc. (\"Parent\"), Hawaii Merger Sub, Inc., a wholly owned subsidiary of  Merck Sharp & Dohme LLC (\"Merger Sub\"), and Harpoon Therapeutics, Inc. (\"Harpoon\"), Merger Sub merged with and into Harpoon (the \"Merger\") on March 11, 2024. Upon completion of the Merger, each share of common stock of Harpoon that was issued and outstanding immediately prior to the effective time of the Merger was cancelled, and each share of common stock of Merger Sub was converted into one share of common stock of the surviving corporation."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(Continued from footnote 1) Consequently, upon the consummation of the Merger on March 11, 2024, Parent became the direct beneficial owner of 1,000 shares of common stock of the surviving corporation, representing 100% of the issued and outstanding shares of common stock of the surviving corporation. Merck & Co., Inc. is the indirect beneficial owner of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of January 7, 2024 by and among Merck Sharp & Dohme LLC, a wholly owned subsidiary of Merck & Co. Inc. (\"Parent\"), Hawaii Merger Sub, Inc., a wholly owned subsidiary of  Merck Sharp & Dohme LLC (\"Merger Sub\"), and Harpoon Therapeutics, Inc. (\"Harpoon\"), Merger Sub merged with and into Harpoon (the \"Merger\") on March 11, 2024. Upon completion of the Merger, each share of common stock of Harpoon that was issued and outstanding immediately prior to the effective time of the Merger was cancelled, and each share of common stock of Merger Sub was converted into one share of common stock of the surviving corporation."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"(Continued from footnote 1) Consequently, upon the consummation of the Merger on March 11, 2024, Parent became the direct beneficial owner of 1,000 shares of common stock of the surviving corporation, representing 100% of the issued and outstanding shares of common stock of the surviving corporation. Merck & Co., Inc. is the indirect beneficial owner of such shares."}],"balance_after":1000,"source":{"system":"sec-edgar","filing":"0000950170-24-029165","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/64978/000095017024029165/ownership.xml","form_type":"4"}},{"id":86315,"issuer":{"id":4115,"kind":"organization","name":"Organon & Co."},"owners":[{"id":2807,"kind":"organization","name":"Merck & Co., Inc.","position":1,"cik":"0000310158","reported_name":"Merck & Co., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-04T20:46:45.000Z","date":"2021-06-02","kind":"other","acquired":false,"shares":253516000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Separation and Distribution Agreement, dated as of June 2, 2021, Merck & Co., Inc. (\"Merck\") distributed to the holders of its common stock by means of a pro-rata distribution without consideration an aggregate of 253,516,000 shares of common stock of Organon & Co. (the \"Separation\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"In connection with the Separation, the 100 shares of common stock of Organon & Co. held by Merck were reclassified into 253,516,000 shares of common stock of Organon & Co."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Separation and Distribution Agreement, dated as of June 2, 2021, Merck & Co., Inc. (\"Merck\") distributed to the holders of its common stock by means of a pro-rata distribution without consideration an aggregate of 253,516,000 shares of common stock of Organon & Co. (the \"Separation\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-022060","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/310158/000089924321022060/doc4.xml","form_type":"4"}},{"id":117654,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":2807,"kind":"organization","name":"Merck & Co., Inc.","position":1,"cik":"0000310158","reported_name":"Merck & Co., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":11928,"kind":"organization","name":"Merck Sharp & Dohme Corp.","position":2,"cik":"0000942443","reported_name":"Merck Sharp & Dohme Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E Convertible Preferred Stock","published_at":"2019-04-09T22:27:04.000Z","date":"2019-04-08","kind":"exercise","acquired":false,"shares":17666666,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series E Convertible Preferred Stock automatically converted into one-half (0.5) of a share of common stock immediately prior to the closing of the Issuer's initial public offering, and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series E Convertible Preferred Stock automatically converted into one-half (0.5) of a share of common stock immediately prior to the closing of the Issuer's initial public offering, and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series E Convertible Preferred Stock automatically converted into one-half (0.5) of a share of common stock immediately prior to the closing of the Issuer's initial public offering, and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are owned directly by Merck Sharp & Dohme Corp., which is a direct, wholly owned subsidiary of Merck & Co., Inc. (\"Merck\"). Merck is an indirect beneficial owner of the reported securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8333333},"source":{"system":"sec-edgar","filing":"0001104659-19-020514","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/310158/000110465919020514/a4.xml","form_type":"4"}},{"id":117653,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":2807,"kind":"organization","name":"Merck & Co., Inc.","position":1,"cik":"0000310158","reported_name":"Merck & Co., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":11928,"kind":"organization","name":"Merck Sharp & Dohme Corp.","position":2,"cik":"0000942443","reported_name":"Merck Sharp & Dohme Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-09T22:27:04.000Z","date":"2019-04-08","kind":"purchase","acquired":true,"shares":4121683,"price":16,"value":65946928.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are owned directly by Merck Sharp & Dohme Corp., which is a direct, wholly owned subsidiary of Merck & Co., Inc. (\"Merck\"). Merck is an indirect beneficial owner of the reported securities."}],"balance_after":12955016,"source":{"system":"sec-edgar","filing":"0001104659-19-020514","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/310158/000110465919020514/a4.xml","form_type":"4"}},{"id":117652,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":2807,"kind":"organization","name":"Merck & Co., Inc.","position":1,"cik":"0000310158","reported_name":"Merck & Co., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":11928,"kind":"organization","name":"Merck Sharp & Dohme Corp.","position":2,"cik":"0000942443","reported_name":"Merck Sharp & Dohme Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-09T22:27:04.000Z","date":"2019-04-08","kind":"exercise","acquired":true,"shares":8833333,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series E Convertible Preferred Stock automatically converted into one-half (0.5) of a share of common stock immediately prior to the closing of the Issuer's initial public offering, and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are owned directly by Merck Sharp & Dohme Corp., which is a direct, wholly owned subsidiary of Merck & Co., Inc. (\"Merck\"). Merck is an indirect beneficial owner of the reported securities."}],"balance_after":8833333,"source":{"system":"sec-edgar","filing":"0001104659-19-020514","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/310158/000110465919020514/a4.xml","form_type":"4"}},{"id":124062,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":2807,"kind":"organization","name":"Merck & Co., Inc.","position":1,"cik":"0000310158","reported_name":"Merck & Co., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":11928,"kind":"organization","name":"Merck Sharp & Dohme Corp.","position":2,"cik":"0000942443","reported_name":"Merck Sharp & Dohme Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E Redeemable Convertible Preferred Stock","published_at":"2018-10-02T18:31:54.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":74794315,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series E redeemable convertible preferred stock (the \"Series E Preferred\") automatically converted into 0.0275 shares of the Issuer's common stock upon the closing of the Issuer's sale of its common stock in its firm commitment underwritten initial public offering pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended. The Series E Preferred had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series E redeemable convertible preferred stock (the \"Series E Preferred\") automatically converted into 0.0275 shares of the Issuer's common stock upon the closing of the Issuer's sale of its common stock in its firm commitment underwritten initial public offering pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended. The Series E Preferred had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series E redeemable convertible preferred stock (the \"Series E Preferred\") automatically converted into 0.0275 shares of the Issuer's common stock upon the closing of the Issuer's sale of its common stock in its firm commitment underwritten initial public offering pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended. The Series E Preferred had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are owned directly by Merck Sharp & Dohme Corp., which is a direct, wholly owned subsidiary of Merck & Co., Inc. (\"Merck\"). Merck is an indirect beneficial owner of the reported securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2056843},"source":{"system":"sec-edgar","filing":"0001104659-18-059933","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/310158/000110465918059933/a4.xml","form_type":"4"}},{"id":124061,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":2807,"kind":"organization","name":"Merck & Co., Inc.","position":1,"cik":"0000310158","reported_name":"Merck & Co., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":11928,"kind":"organization","name":"Merck Sharp & Dohme Corp.","position":2,"cik":"0000942443","reported_name":"Merck Sharp & Dohme Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T18:31:54.000Z","date":"2018-10-01","kind":"purchase","acquired":true,"shares":666666,"price":15,"value":9999990.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are owned directly by Merck Sharp & Dohme Corp., which is a direct, wholly owned subsidiary of Merck & Co., Inc. (\"Merck\"). Merck is an indirect beneficial owner of the reported securities."}],"balance_after":2723509,"source":{"system":"sec-edgar","filing":"0001104659-18-059933","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/310158/000110465918059933/a4.xml","form_type":"4"}},{"id":124060,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":2807,"kind":"organization","name":"Merck & Co., Inc.","position":1,"cik":"0000310158","reported_name":"Merck & Co., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":11928,"kind":"organization","name":"Merck Sharp & Dohme Corp.","position":2,"cik":"0000942443","reported_name":"Merck Sharp & Dohme Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T18:31:54.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":2056843,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series E redeemable convertible preferred stock (the \"Series E Preferred\") automatically converted into 0.0275 shares of the Issuer's common stock upon the closing of the Issuer's sale of its common stock in its firm commitment underwritten initial public offering pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended. The Series E Preferred had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are owned directly by Merck Sharp & Dohme Corp., which is a direct, wholly owned subsidiary of Merck & Co., Inc. (\"Merck\"). Merck is an indirect beneficial owner of the reported securities."}],"balance_after":2056843,"source":{"system":"sec-edgar","filing":"0001104659-18-059933","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/310158/000110465918059933/a4.xml","form_type":"4"}},{"id":132854,"issuer":{"id":9776,"kind":"organization","name":"CapForce Inc."},"owners":[{"id":2807,"kind":"organization","name":"Merck & Co., Inc.","position":1,"cik":"0000310158","reported_name":"Merck & Co., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":11928,"kind":"organization","name":"Merck Sharp & Dohme Corp.","position":2,"cik":"0000942443","reported_name":"Merck Sharp & Dohme Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12193,"kind":"organization","name":"Merck Global Health Innovation Fund, LLC","position":3,"cik":"0001547132","reported_name":"Merck Global Health Innovation Fund, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2018-02-08T21:05:50.000Z","date":"2017-06-28","kind":"grant","acquired":true,"shares":13120,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These amounts reflect the Issuer's recently announced and effectuated a 1 for 25 reverse stock split on January 17, 2018."},{"field":"shares","element":"transactionShares","label":"F1","text":"These amounts reflect the Issuer's recently announced and effectuated a 1 for 25 reverse stock split on January 17, 2018."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"These amounts reflect the Issuer's recently announced and effectuated a 1 for 25 reverse stock split on January 17, 2018."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These amounts reflect the Issuer's recently announced and effectuated a 1 for 25 reverse stock split on January 17, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are owned directly by Merck Global Health Innovation Fund, LLC (\"MGHIF\"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. (\"MSD\"), which is a wholly owned subsidiary of Merck & Co., Inc. (\"Merck\").  MSD and Merck are indirect beneficial owners of the reported securities."}],"balance_after":13120,"derivative":{"exercise_price":19.5,"exercise_date":"2018-01-28","expiration_date":"2022-06-28","underlying":"Common Stock","underlying_shares":13120},"source":{"system":"sec-edgar","filing":"0000899243-18-003274","document":"doc5.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/310158/000089924318003274/doc5.xml","form_type":"5"}},{"id":151545,"issuer":{"id":9776,"kind":"organization","name":"CapForce Inc."},"owners":[{"id":2807,"kind":"organization","name":"Merck & Co., Inc.","position":1,"cik":"0000310158","reported_name":"Merck & Co., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":11928,"kind":"organization","name":"Merck Sharp & Dohme Corp.","position":2,"cik":"0000942443","reported_name":"Merck Sharp & Dohme Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12193,"kind":"organization","name":"Merck Global Health Innovation Fund, LLC","position":3,"cik":"0001547132","reported_name":"Merck Global Health Innovation Fund, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2016-06-29T20:05:50.000Z","date":"2016-06-27","kind":"purchase","acquired":true,"shares":2050821,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were included within units (\"Units\") with each Unit consisting of one share of the Company's common stock, par value $0.01 per share (the \"Common Stock\") and (ii) a warrant to acquire 0.75 of one share of Common Stock for a purchase price of $1.14375 per Unit."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are owned directly by Merck Global Health Innovation Fund, LLC (\"MGHIF\"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. (\"MSD\"), which is a wholly owned subsidiary of Merck & Co., Inc. (\"Merck\").  MSD and Merck are indirect beneficial owners of the reported securities."}],"balance_after":2950821,"derivative":{"exercise_price":1.3125,"exercise_date":"2016-09-27","expiration_date":"2021-06-27","underlying":"Common Stock","underlying_shares":2050821},"source":{"system":"sec-edgar","filing":"0000899243-16-023850","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/310158/000089924316023850/doc4.xml","form_type":"4"}},{"id":151544,"issuer":{"id":9776,"kind":"organization","name":"CapForce Inc."},"owners":[{"id":2807,"kind":"organization","name":"Merck & Co., Inc.","position":1,"cik":"0000310158","reported_name":"Merck & Co., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":11928,"kind":"organization","name":"Merck Sharp & Dohme Corp.","position":2,"cik":"0000942443","reported_name":"Merck Sharp & Dohme Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12193,"kind":"organization","name":"Merck Global Health Innovation Fund, LLC","position":3,"cik":"0001547132","reported_name":"Merck Global Health Innovation Fund, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-06-29T20:05:50.000Z","date":"2016-06-27","kind":"grant","acquired":true,"shares":2734427,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were included within units (\"Units\") with each Unit consisting of one share of the Company's common stock, par value $0.01 per share (the \"Common Stock\") and (ii) a warrant to acquire 0.75 of one share of Common Stock for a purchase price of $1.14375 per Unit."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are owned directly by Merck Global Health Innovation Fund, LLC (\"MGHIF\"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. (\"MSD\"), which is a wholly owned subsidiary of Merck & Co., Inc. (\"Merck\").  MSD and Merck are indirect beneficial owners of the reported securities."}],"balance_after":5413449,"source":{"system":"sec-edgar","filing":"0000899243-16-023850","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/310158/000089924316023850/doc4.xml","form_type":"4"}},{"id":152357,"issuer":{"id":9776,"kind":"organization","name":"CapForce Inc."},"owners":[{"id":2807,"kind":"organization","name":"Merck & Co., Inc.","position":1,"cik":"0000310158","reported_name":"Merck & Co., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":11928,"kind":"organization","name":"Merck Sharp & Dohme Corp.","position":2,"cik":"0000942443","reported_name":"Merck Sharp & Dohme Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12193,"kind":"organization","name":"Merck Global Health Innovation Fund, LLC","position":3,"cik":"0001547132","reported_name":"Merck Global Health Innovation Fund, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock and Warrants (Obligation to buy Units)","published_at":"2016-05-24T20:41:15.000Z","date":"2016-05-19","kind":"purchase","acquired":true,"shares":2734427,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents future obligation of MGHIF to purchase additional Units for a purchase price of $1.14375 per Unit within 60 days and subject to stockholder consent and notice to stockholders of same (including the filing of Schedule 14C and the twenty day waiting period), pursuant to the Amended and Restated Securities Purchase Agreement entered into on May 18, 2016."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents future obligation of MGHIF to purchase additional Units for a purchase price of $1.14375 per Unit within 60 days and subject to stockholder consent and notice to stockholders of same (including the filing of Schedule 14C and the twenty day waiting period), pursuant to the Amended and Restated Securities Purchase Agreement entered into on May 18, 2016."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents future obligation of MGHIF to purchase additional Units for a purchase price of $1.14375 per Unit within 60 days and subject to stockholder consent and notice to stockholders of same (including the filing of Schedule 14C and the twenty day waiting period), pursuant to the Amended and Restated Securities Purchase Agreement entered into on May 18, 2016."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Merck Global Health Innovation Fund, LLC (\"MGHIF\"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. (\"MSD\"), which is a wholly owned subsidiary of Merck & Co., Inc. (\"Merck\").  MSD and Merck are indirect beneficial owners of the reported securities."}],"balance_after":5685248,"derivative":{"exercise_price":1.1438,"underlying":"Common Stock","underlying_shares":4785248},"source":{"system":"sec-edgar","filing":"0000899243-16-020819","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/310158/000089924316020819/doc4.xml","form_type":"4"}},{"id":152356,"issuer":{"id":9776,"kind":"organization","name":"CapForce Inc."},"owners":[{"id":2807,"kind":"organization","name":"Merck & Co., Inc.","position":1,"cik":"0000310158","reported_name":"Merck & Co., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":11928,"kind":"organization","name":"Merck Sharp & Dohme Corp.","position":2,"cik":"0000942443","reported_name":"Merck Sharp & Dohme Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12193,"kind":"organization","name":"Merck Global Health Innovation Fund, LLC","position":3,"cik":"0001547132","reported_name":"Merck Global Health Innovation Fund, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2016-05-24T20:41:15.000Z","date":"2016-05-19","kind":"purchase","acquired":true,"shares":900000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within units (\"Units\") each Unit consisting of one share of the Company's common stock, par value $0.01 per share (the \"Common Stock\") and (ii) a warrant to acquire 0.75 of one share of Common Stock for a purchase price of $1.14375 per Unit."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Merck Global Health Innovation Fund, LLC (\"MGHIF\"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. (\"MSD\"), which is a wholly owned subsidiary of Merck & Co., Inc. (\"Merck\").  MSD and Merck are indirect beneficial owners of the reported securities."}],"balance_after":900000,"derivative":{"exercise_price":1.3125,"exercise_date":"2016-08-17","expiration_date":"2021-05-19","underlying":"Common Stock","underlying_shares":900000},"source":{"system":"sec-edgar","filing":"0000899243-16-020819","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/310158/000089924316020819/doc4.xml","form_type":"4"}},{"id":152355,"issuer":{"id":9776,"kind":"organization","name":"CapForce Inc."},"owners":[{"id":2807,"kind":"organization","name":"Merck & Co., Inc.","position":1,"cik":"0000310158","reported_name":"Merck & Co., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":11928,"kind":"organization","name":"Merck Sharp & Dohme Corp.","position":2,"cik":"0000942443","reported_name":"Merck Sharp & Dohme Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12193,"kind":"organization","name":"Merck Global Health Innovation Fund, LLC","position":3,"cik":"0001547132","reported_name":"Merck Global Health Innovation Fund, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-05-24T20:41:15.000Z","date":"2016-05-19","kind":"grant","acquired":true,"shares":1200000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within units (\"Units\") each Unit consisting of one share of the Company's common stock, par value $0.01 per share (the \"Common Stock\") and (ii) a warrant to acquire 0.75 of one share of Common Stock for a purchase price of $1.14375 per Unit."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Merck Global Health Innovation Fund, LLC (\"MGHIF\"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. (\"MSD\"), which is a wholly owned subsidiary of Merck & Co., Inc. (\"Merck\").  MSD and Merck are indirect beneficial owners of the reported securities."}],"balance_after":2679022,"source":{"system":"sec-edgar","filing":"0000899243-16-020819","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/310158/000089924316020819/doc4.xml","form_type":"4"}},{"id":156514,"issuer":{"id":2168,"kind":"organization","name":"BeOne Medicines Ltd.","symbol":"ONC"},"owners":[{"id":2807,"kind":"organization","name":"Merck & Co., Inc.","position":1,"cik":"0000310158","reported_name":"Merck & Co., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":11928,"kind":"organization","name":"Merck Sharp & Dohme Corp.","position":2,"cik":"0000942443","reported_name":"Merck Sharp & Dohme Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12427,"kind":"organization","name":"Merck Sharp & Dohme Research GmbH","position":3,"cik":"0001665244","reported_name":"Merck Sharp & Dohme Research GmbH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Shares","published_at":"2016-02-10T21:28:20.000Z","date":"2016-02-08","kind":"exercise","acquired":false,"shares":5128205,"ownership":{"direct":false,"nature":"Via wholly owned subsidiary, MSDRG"},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH (\"MSDRG\"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. (\"MSD\"), which is a wholly owned subsidiary of Merck & Co., Inc. (\"Merck\"). MSD and Merck are indirect beneficial owners of the reported securities."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Shares (the \"Series A Shares\") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Shares (the \"Series A Shares\") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series A-2 Preferred Shares (the \"Series A-2 Shares\") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A-2 Shares did not have an expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A-2 Preferred Shares (the \"Series A-2 Shares\") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A-2 Shares did not have an expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH (\"MSDRG\"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. (\"MSD\"), which is a wholly owned subsidiary of Merck & Co., Inc. (\"Merck\"). MSD and Merck are indirect beneficial owners of the reported securities."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":5128205},"source":{"system":"sec-edgar","filing":"0001635698-16-000062","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/310158/000163569816000062/form4.xml","form_type":"4"}},{"id":156513,"issuer":{"id":2168,"kind":"organization","name":"BeOne Medicines Ltd.","symbol":"ONC"},"owners":[{"id":2807,"kind":"organization","name":"Merck & Co., Inc.","position":1,"cik":"0000310158","reported_name":"Merck & Co., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":11928,"kind":"organization","name":"Merck Sharp & Dohme Corp.","position":2,"cik":"0000942443","reported_name":"Merck Sharp & Dohme Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12427,"kind":"organization","name":"Merck Sharp & Dohme Research GmbH","position":3,"cik":"0001665244","reported_name":"Merck Sharp & Dohme Research GmbH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Shares","published_at":"2016-02-10T21:28:20.000Z","date":"2016-02-08","kind":"exercise","acquired":false,"shares":18518519,"ownership":{"direct":false,"nature":"Via wholly owned subsidiary, MSDRG"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Shares (the \"Series A Shares\") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Shares (the \"Series A Shares\") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Shares (the \"Series A Shares\") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Shares (the \"Series A Shares\") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH (\"MSDRG\"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. (\"MSD\"), which is a wholly owned subsidiary of Merck & Co., Inc. (\"Merck\"). MSD and Merck are indirect beneficial owners of the reported securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH (\"MSDRG\"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. (\"MSD\"), which is a wholly owned subsidiary of Merck & Co., Inc. (\"Merck\"). MSD and Merck are indirect beneficial owners of the reported securities."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":18518519},"source":{"system":"sec-edgar","filing":"0001635698-16-000062","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/310158/000163569816000062/form4.xml","form_type":"4"}},{"id":156512,"issuer":{"id":2168,"kind":"organization","name":"BeOne Medicines Ltd.","symbol":"ONC"},"owners":[{"id":2807,"kind":"organization","name":"Merck & Co., Inc.","position":1,"cik":"0000310158","reported_name":"Merck & Co., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":11928,"kind":"organization","name":"Merck Sharp & Dohme Corp.","position":2,"cik":"0000942443","reported_name":"Merck Sharp & Dohme Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12427,"kind":"organization","name":"Merck Sharp & Dohme Research GmbH","position":3,"cik":"0001665244","reported_name":"Merck Sharp & Dohme Research GmbH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2016-02-10T21:28:20.000Z","date":"2016-02-08","kind":"other","acquired":true,"shares":7942314,"ownership":{"direct":false,"nature":"Via wholly owned subsidiary, MSDRG"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The 7,942,314 Ordinary Shares were issued to MSDRG in exchange for the cancellation of MSDRG's promissory note plus accrued and unpaid interest thereon (together, $14,693,281)(the \"Note Exchange Amount\") upon the closing of the initial public offering of the Issuer. The number of shares issued was determined by dividing the Note Exchange Amount by the initial public offering share price of $1.85."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The 7,942,314 Ordinary Shares were issued to MSDRG in exchange for the cancellation of MSDRG's promissory note plus accrued and unpaid interest thereon (together, $14,693,281)(the \"Note Exchange Amount\") upon the closing of the initial public offering of the Issuer. The number of shares issued was determined by dividing the Note Exchange Amount by the initial public offering share price of $1.85."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH (\"MSDRG\"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. (\"MSD\"), which is a wholly owned subsidiary of Merck & Co., Inc. (\"Merck\"). MSD and Merck are indirect beneficial owners of the reported securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH (\"MSDRG\"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. (\"MSD\"), which is a wholly owned subsidiary of Merck & Co., Inc. (\"Merck\"). MSD and Merck are indirect beneficial owners of the reported securities."}],"balance_after":7942314,"source":{"system":"sec-edgar","filing":"0001635698-16-000062","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/310158/000163569816000062/form4.xml","form_type":"4"}},{"id":156511,"issuer":{"id":2168,"kind":"organization","name":"BeOne Medicines Ltd.","symbol":"ONC"},"owners":[{"id":2807,"kind":"organization","name":"Merck & Co., Inc.","position":1,"cik":"0000310158","reported_name":"Merck & Co., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":11928,"kind":"organization","name":"Merck Sharp & Dohme Corp.","position":2,"cik":"0000942443","reported_name":"Merck Sharp & Dohme Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12427,"kind":"organization","name":"Merck Sharp & Dohme Research GmbH","position":3,"cik":"0001665244","reported_name":"Merck Sharp & Dohme Research GmbH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2016-02-10T21:28:20.000Z","date":"2016-02-08","kind":"exercise","acquired":true,"shares":5128205,"ownership":{"direct":false,"nature":"Via wholly owned subsidiary, MSDRG"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series A-2 Preferred Shares (the \"Series A-2 Shares\") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A-2 Shares did not have an expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH (\"MSDRG\"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. (\"MSD\"), which is a wholly owned subsidiary of Merck & Co., Inc. (\"Merck\"). MSD and Merck are indirect beneficial owners of the reported securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH (\"MSDRG\"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. (\"MSD\"), which is a wholly owned subsidiary of Merck & Co., Inc. (\"Merck\"). MSD and Merck are indirect beneficial owners of the reported securities."}],"balance_after":5128205,"source":{"system":"sec-edgar","filing":"0001635698-16-000062","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/310158/000163569816000062/form4.xml","form_type":"4"}},{"id":156510,"issuer":{"id":2168,"kind":"organization","name":"BeOne Medicines Ltd.","symbol":"ONC"},"owners":[{"id":2807,"kind":"organization","name":"Merck & Co., Inc.","position":1,"cik":"0000310158","reported_name":"Merck & Co., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":11928,"kind":"organization","name":"Merck Sharp & Dohme Corp.","position":2,"cik":"0000942443","reported_name":"Merck Sharp & Dohme Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12427,"kind":"organization","name":"Merck Sharp & Dohme Research GmbH","position":3,"cik":"0001665244","reported_name":"Merck Sharp & Dohme Research GmbH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2016-02-10T21:28:20.000Z","date":"2016-02-08","kind":"exercise","acquired":true,"shares":18518519,"ownership":{"direct":false,"nature":"Via wholly owned subsidiary, MSDRG"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Shares (the \"Series A Shares\") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH (\"MSDRG\"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. (\"MSD\"), which is a wholly owned subsidiary of Merck & Co., Inc. (\"Merck\"). MSD and Merck are indirect beneficial owners of the reported securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH (\"MSDRG\"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. (\"MSD\"), which is a wholly owned subsidiary of Merck & Co., Inc. (\"Merck\"). MSD and Merck are indirect beneficial owners of the reported securities."}],"balance_after":18518519,"source":{"system":"sec-edgar","filing":"0001635698-16-000062","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/310158/000163569816000062/form4.xml","form_type":"4"}}]}